Compare ADMA Biologics Inc (ADMA) vs Paycom Software Inc (PAYC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Paycom Software Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Paycom Software Inc trades at $138.33 (market cap $6.70B). The key difference: Paycom Software Inc is far larger — about 3.1× ADMA Biologics Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PAYC | |
|---|---|---|
Market Cap | $2.13B | $6.70B |
Sector | Health | Technology |
52-Week High | $20.38 | $238.80 |
52-Week Low | $7.60 | $113.59 |
Enterprise Value | $2.20B | $7.31B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Paycom Software (PAYC) trades at $143.78, up 3.28% on the day, with a bullish technical signal and strong fundamentals including a 22.44% net income margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $678.9 million in 2025. Analyst consensus is mixed with a $151 price target, while recent news highlights its value stock appeal and industry awards.
The outlook for PAYC is positive with solid revenue growth and profitability, though risks include competitive pressures and market volatility. The stock's current valuation metrics, such as a P/E of 16.19, suggest room for upside if earnings momentum continues, but investors should weigh execution risks against the bullish analyst sentiment and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
